Celltrion has shipped the first batch of Inflectra, a biosimilar of Johnson & Johnson's Remicade, to the US, The Korea Times reported Friday.
The company is accelerating the launch of the therapy after winning a patent infringement lawsuit regarding the drug.
Pfizer will be responsible for marketing Inflectra, which is sold under the name Remsima in Europe, in the US.
"There remain more procedures before the biosimilar medicine actually hits the US market," a Celltrion official stated, adding "Pfizer will put forth efforts to deal with them although we will keep cooperating. We believe that our victory in the patent suit cleared the biggest hurdle, which prompted us to start shipment."
Remicade had sales of $4.5 billion in the US and $9.9 billion globally in 2015.
"Based on the trust of European physicians and patients, we expect that penetration into the US market will take place at a much faster pace," Celltrion stated.
To read more NewsPoints articles, click here.